Valrox Valoctocogene Roxaparvovec Emerging Drug Insight And Market Forecast

“Valrox (Valoctocogene Roxaparvovec)- Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Haemophilia A in 7 Major Markets. A detailed picture of the VALROX (VALOCTOCOGENE ROXAPARVOVEC) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary

Valoctocogene roxaparvovec, is an investigational gene therapy in clinical trials for the treatment of Hemophilia A and has not been determined to be safe or effective. Valoctocogene roxaparvovec is administered as a single infusion. The ongoing clinical trials will determine if the new gene will enable the body to produce factor VIII. Following infusion, clinical trial subjects are being evaluated to determine the safety profile, changes in Factor VIII activity levels, changes in factor replacement usage, changes in reported bleeds requiring factor replacement, and quality of life measures, among other endpoints. The current standard of care for most hemophilia A patients who are severely affected today is a prophylactic regimen of intravenous infusions three times per week. Even with prophylactic regimens, many patients still experience spontaneous bleeding events.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around VALROX (VALOCTOCOGENE ROXAPARVOVEC).
  • The report contains forecasted sales for VALROX (VALOCTOCOGENE ROXAPARVOVEC) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Haemophilia A.
  • The report also features the SWOT analysis with analyst insights and key findings of VALROX (VALOCTOCOGENE ROXAPARVOVEC).


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VALROX (VALOCTOCOGENE ROXAPARVOVEC) Analytical Perspective by DelveInsight


This report provides a detailed market assessment of VALROX (VALOCTOCOGENE ROXAPARVOVEC) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.


The report provides the clinical trials information of VALROX (VALOCTOCOGENE ROXAPARVOVEC) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights  

  • In the coming years, the market scenario for Haemophilia A is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
  • The companies and academics are working to assess challenges and seek opportunities that could influence VALROX (VALOCTOCOGENE ROXAPARVOVEC) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Haemophilia A are giving market competition to VALROX (VALOCTOCOGENE ROXAPARVOVEC) and launch of late-stage emerging therapies in the near future will significantly impact the market.  
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of VALROX (VALOCTOCOGENE ROXAPARVOVEC).
  • Our in-depth analysis of the forecasted sales data of VALROX (VALOCTOCOGENE ROXAPARVOVEC) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VALROX (VALOCTOCOGENE ROXAPARVOVEC). 

Key Questions

  • Which company is developing VALROX (VALOCTOCOGENE ROXAPARVOVEC) along with the phase of the clinical study?
  • What is the technology utilized in the development of VALROX (VALOCTOCOGENE ROXAPARVOVEC)?
  • What is the product type, route of administration and mechanism of action of VALROX (VALOCTOCOGENE ROXAPARVOVEC)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VALROX (VALOCTOCOGENE ROXAPARVOVEC) development?
  • What are the key designations that have been granted to VALROX (VALOCTOCOGENE ROXAPARVOVEC)?
  • What is the forecasted market scenario of VALROX (VALOCTOCOGENE ROXAPARVOVEC)?
  • What is the history of VALROX (VALOCTOCOGENE ROXAPARVOVEC) and what is its future?
  • What is the forecasted sales of VALROX (VALOCTOCOGENE ROXAPARVOVEC) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
  • What are the other emerging products available and how these are giving competition to VALROX (VALOCTOCOGENE ROXAPARVOVEC)?
  • Which are the late-stage emerging therapies under development for the treatment of the Hemophilia A?

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assesment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Table


Table 2 VALROX (VALOCTOCOGENE ROXAPARVOVEC), Clinical Trial Description

Table 3 VALROX (VALOCTOCOGENE ROXAPARVOVEC), 7MM Market Size from 2020 to 2030 (in Million USD)

Table 4 Market Competitors

Table 5 Other Emerging Therapies

List of Figure

 Figure 1 The Development Timeline of VALROX (VALOCTOCOGENE ROXAPARVOVEC)


Figure 3 VALROX (VALOCTOCOGENE ROXAPARVOVEC), 7MM Market Size from 2020 to 2030 (in Million USD)

Figure 4 VALROX (VALOCTOCOGENE ROXAPARVOVEC), US Market Size from 2020 to 2030 (in Millions USD)

Figure 5 VALROX (VALOCTOCOGENE ROXAPARVOVEC), EU5 Market Size from 2020 to 2030 (in Millions USD)

Figure 6 VALROX (VALOCTOCOGENE ROXAPARVOVEC), Japan Market Size from 2020 to 2030 (in Millions USD)

  • Tags:
  • "Valrox (Valoctocogene Roxaparvovec...
  • Valrox (Valoctocogene Roxaparvovec...
  • Valrox (Valoctocogene Roxaparvovec...
  • Valrox (Valoctocogene Roxaparvovec...
  • Valrox (Valoctocogene Roxaparvovec)...
  • Valrox (Valoctocogene Roxaparvovec)...
  • Valrox (Valoctocogene Roxaparvovec)...
  • Valrox (Valoctocogene Roxaparvovec)...
  • Valrox (Valoctocogene Roxaparvovec...
  • Valrox (Valoctocogene Roxaparvovec...

Forward to Friend

Need A Quote